Department of Medicine, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
J Biol Chem. 2013 Jul 12;288(28):20326-33. doi: 10.1074/jbc.M113.484550. Epub 2013 Jun 3.
The P-glycoprotein drug pump protects us from toxins. Drug-binding sites in the transmembrane (TM) domains (TMDs) are connected to the nucleotide-binding domains (NBDs) by intracellular helices (IHs). TMD-NBD cross-talk is a key step in the transport mechanism because drug binding stimulates ATP hydrolysis followed by drug efflux. Here, we tested whether the IHs are critical for maturation and TMD-NBD coupling by characterizing the effects of mutations to the IH1 and IH2 interfaces. Although IH1 mutations had little effect, most mutations at the IH2-NBD2 interface inhibited maturation or activity. For example, the F1086A mutation at the IH2-NBD2 interface abolished drug-stimulated ATPase activity. The mutant F1086A, however, retained the ability to bind ATP and drug substrates. The mutant was defective in mediating ATP-dependent conformational changes in the TMDs because binding of ATP no longer promoted cross-linking between cysteines located at the extracellular ends of TM segments 6 and 12. Replacement of Phe-1086 (in NBD2) with hydrophobic but not charged residues yielded active mutants. The activity of the F1086A mutant could be restored when the nearby residue Ala-266 (in IH2) was replaced with aromatic residues. These results suggest that Ala-266/Phe-1086 lies in a hydrophobic IH2-NBD2 "ball-and-socket" joint.
P-糖蛋白药物泵可保护我们免受毒素侵害。跨膜(TM)结构域(TMD)中的药物结合位点通过细胞内螺旋(IH)与核苷酸结合结构域(NBD)相连。TMD-NBD 串扰是转运机制中的关键步骤,因为药物结合会刺激 ATP 水解,随后药物外排。在这里,我们通过对 IH1 和 IH2 界面突变的影响进行特征分析,测试了 IH 是否对成熟和 TMD-NBD 偶联至关重要。尽管 IH1 突变影响较小,但 IH2-NBD2 界面的大多数突变会抑制成熟或活性。例如,在 IH2-NBD2 界面的 F1086A 突变会使药物刺激的 ATP 酶活性丧失。然而,突变体仍然保留结合 ATP 和药物底物的能力。突变体在介导 TMD 中的 ATP 依赖性构象变化方面存在缺陷,因为结合 ATP 不再促进位于 TM 片段 6 和 12 细胞外末端的半胱氨酸之间的交联。用疏水性但非带电残基取代 NBD2 中的苯丙氨酸-1086(Phe-1086)会产生具有活性的突变体。当附近的残基 Ala-266(在 IH2 中)被芳香族残基取代时,F1086A 突变体的活性可以恢复。这些结果表明,Ala-266/Phe-1086 位于疏水性 IH2-NBD2“球窝”接头中。